News Oncology Pharma Inc.

Equities

ONPH

US68235J2015

Market Closed - OTC Markets Other stock markets 09:00:50 15/05/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		+49,99,900.00%	-50.00%

2021	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
2021	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	12/22/12	PU
Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	29/22/29	PU
Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	06/22/06	PU
Oncology Pharma : Financial Statements for the period ended December 31, 2021	15/22/15	PU
Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	15/22/15	PU
Oncology Pharma Inc :.	20/21/20	AQ
Oncology Pharma : Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities	31/21/31	AQ
NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	31/21/31	CI
Oncology Pharma : Reveals Strategic Plans for Company Growth and Focus	16/21/16	AQ
Oncology Pharma : Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	10/21/10	AQ
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	10/21/10	CI
Oncology Pharma : Moves to Fund Lead Drug Formulation & IND-Enabling Studies	04/21/04	AQ
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	04/21/04	CI
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	26/21/26	GL
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	26/21/26	CI
Oncology Pharma : Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology	22/21/22	AQ
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	22/21/22	CI
Oncology Pharma : is Pleased to Welcome New Chairman to Its Scientific Advisory Board	16/21/16	AQ
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	16/21/16	CI
Oncology Pharma : Renews Licensing Agreement With Ribera Solutions LLC for Its Connect2Med Clinical Trials Platform	09/21/09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncology Pharma Inc.

Equities

ONPH

US68235J2015

Summary

Filters